Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
Goldman Sachs builds its Conviction List by identifying stocks where analysts hold their highest confidence in outperformance, and this month's screen turned up five dividend payers with yields that income investors rarely find attached…
Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.
XLC carries the word "communication" in its name, but the fund's actual portfolio has almost nothing to do with phone bills, fiber lines, or fat dividend checks. Before you assume you own telecom income,…
Rocket Lab's stock has shed more than half its value from its peak while analysts pile on buy ratings and one major bank sees the price doubling. Something has to give, and the answer…
HPE and Snowflake report earnings the same night, forcing a direct choice between two very different bets on enterprise tech. For retirement-focused investors, the gap between these two stocks runs much deeper than dividends…
REM's 9% yield looks irresistible until you check what a decade of collecting those distributions actually did to your principal. Three equity REITs expose the structural flaw and offer a cleaner path to real…
Certain high-yield investments quietly hand thousands of dollars to the IRS every single year, and most investors holding them in taxable accounts have never stopped to calculate exactly how much they are surrendering before…
Trump is cheering on the AI data center boom as a golden goose, but the CEOs of Apple, Amazon, and Micron are quietly confirming what millions of families already sense at the checkout counter…
Wall Street analysts reshuffled their ratings on September 1st with some dramatic target price swings, including one major utility stock getting its target slashed nearly in half while a red-hot language app saw its…
Retail investors have been piling into Nvidia for 15 straight trading sessions, and after a quarter that shattered nearly every estimate on the board, Wall Street is asking whether the buying frenzy has any…
Broadcom and Marvell both design custom chips for the same hyperscaler clients, both raised their outlooks, and both trade on the AI ASIC boom. So why do their risk profiles, valuations, and investor theses…
Palantir posted record software growth while Intel staged its biggest revenue comeback in fifteen years, and choosing between them for the second half of 2026 comes down to a single uncomfortable question about valuation…
Palantir runs elite software margins while Intel bleeds billions building fabs, yet one of them looks like the smarter trade for the next four months and the answer is not the obvious one.
Institutional money flooded into Bitcoin ETFs at a pace not seen since last October's flash crash, yet retail investors barely noticed. Understanding where that billion-dollar weekly bid came from reveals exactly how fragile this…
